bipolar disorder

Valproic Acid (2-Propylpentanoic Acid) is an HDAC inhibitor that suppresses HDAC1 activity and induces HDAC2 degradation, exhibiting oral bioavailability. Valproic Acid activates Notch1 signalling and inhibits the proliferation of small cell lung carcinoma cells, making it applicable for research into epilepsy and bipolar disorder.

JNJ-37822681 has potential for the treatment of schizophrenia and bipolar disorder.JNJ-37822681 dihydrochloride is a potent, specific, centrally active, fast-dissociating dopamine D2 receptor antagonist with a moderate binding affinity for the dopamine D2

Valproic acid sodium salt (Sodium Valproate) is the sodium salt form of valproic acid with anti-epileptic activity. Valproic acid sodium salt is converted into its active form, valproate ion, in blood. Although the mechanism of action remains to be elucidated, Valproic acid sodium salt increases concentrations of gamma-aminobutyric acid (GABA) in the brain, probably due to inhibition of the enzymes responsible for the catabolism of GABA. This potentiates the synaptic actions of GABA. Valproic acid sodium salt may also affect potassium channels, thereby creating a direct membrane-stabilizing effect.

Divalproex Sodium (Valproate semisodium) binds to and inhibits gamma-aminobutyric acid (GABA) transaminase and its anticonvulsant activity may be exerted by increasing brain concentration of GABA and by inhibiting enzymes that catabolize GABA or block the reuptake of GABA into glia and nerve endings. It also is an HDAC inhibitor, Comprised of sodium valproate and valproic acid with anticonvulsant and antiepileptic activities. Divalproex may also work by suppressing repetitive neuronal firing through the inhibition of voltage-sensitive sodium channels.

SLV-310 is a potent dopamine D2 receptor antagonist and 5-HT reuptake receptor inhibitor used in the study of neurological disorders such as bipolar disorder and schizophrenia.

Lensiprazine (SLV314) is a potent dopamine D(2) receptor antagonist that acts as a serotonin reuptake inhibitor , and can be used to study bipolar disorder and schizophrenia.

Lurasidone hydrochloride (Lurasidone HCl) is a thiazole derivative and atypical antipsychotic agent that functions as a dopamine D2 receptor antagonist; serotonin 5-HT2 receptor antagonist, serotonin 5-HT7 receptor antagonist, an antagonist of the adrenergic α2A and α2C receptors, as well as a partial serotonin 5-HT1A receptor agonist. It is used in the treatment of schizophrenia and bipolar disorder.

Asenapine Maleate (Org 5222 maleate) is a second generation (atypical) antipsychotic agent that is taken sublingually and used in the treatment of schizophrenia and manic or mixed episodes associated with bipolar 1 disorder. Asenapine is associated with a low rate of transient and mild serum aminotransferase elevations during therapy but has not been linked to instances of clinically apparent acute liver injury.

Raxatrigine (CNV 1014802) has been investigated for the treatment of Bipolar Disorder and Bipolar Depression.

Quetiapine (ICI204636) is used for the therapy of schizophrenia, and for the treatment of acute manic episodes associated with bipolar I disorder. The mechanism of quetiapine' action is thought by mediated through antagonist activity at serotonin and dopamine receptors. Specifically, the D1 and D2 dopamine, the α1 adrenoreceptor and α2 adrenoreceptor, and 5-HT1A and 5-HT2 serotonin receptor subtypes are antagonized. Quetiapine also can inhibit the histamine H1 receptor.

5-HT2A receptor agonist-8 (compound 8) is a potent 5-HT2A receptor agonist with an EC50 of 0.6784 nM. It is suitable for research related to depression and bipolar disorder.

ARN25657 is a dual regulator of D3R/GSK-3β. It demonstrates partial agonist activity at the D3 receptor (EC50 = 15.2 nM, Ki = 1.5 nM) alongside potent inhibitor activity against GSK-3β (IC50 = 19.3 nM). ARN25657 shows excellent GSK-3β selectivity over FYN, PKA, and CDK5/p35. It inhibits P-gp-mediated efflux of acetoxymethyl calcein, enhancing in vitro ADME properties while maintaining balanced dual-target distribution. ARN25657 is applicable in the study of bipolar disorder and related neuropsychiatric conditions.

Asenapine (Org 5222) is a 5-HT receptor, adrenergic receptor, dopamine receptor, and histamine receptor antagonist with antipsychotic effects that is used to treat schizophrenia and manic or mixed episodes associated with bipolar 1 disorder.721483-46-5

Thioproperazine (RP 7843) is an orally effective antipsychotic also used as a tranquilizer and antiemetic for the treatment of schizophrenia and the manic phase of bipolar disorder, acting as a histamine and adrenergic receptor blocker.

Asenapine hydrochloride (Org 5222 hydrochloride) is a 5-hydroxytryptamine receptor, adrenergic receptor, dopamine receptor and histamine receptor antagonist with antipsychotic effects used in neurological disorders such as schizophrenia and bipolar disorder.

Aripiprazole cavoxil is used in Treatment of Schizophrenia, Bipolar Disorder, and Clinical Depression.

GSK-3β inhibitor 6 is a highly potent inhibitor of GSK-3β with an IC50 value of 24.4 μM, significantly enhancing hepatocyte glucose uptake (38%). This compound holds great potential for studying diseases such as diabetes, inflammation, cancer, Alzheimer's disease, and bipolar disorder [1].

Asenapine citrate is an atypical antipsychotic drug and is a 5-hydroxytryptamine receptor (pKi: 8.4-10.5), adrenoceptor (pKi: 8.9-9.5), dopamine receptor (pKi: 8.9-9.4), and histamine receptor (pKi: 8.2-9.0) antagonists of multiple receptors. Asenapine citrate can be used to study schizophrenia and bipolar disorder.

GSK-3β inhibitor 7 is a GSK-3β inhibitor (IC50: 5.25 μM) that acts by inserting into the ATP-binding pocket of GSK-3β and forming hydrogen bonds. It exhibits a high rate of glucose uptake by hepatocytes (83.5%) and can be used to study various diseases such as cancer, diabetes, inflammation, Alzheimer's disease, and bipolar disorder.

Olanzapine HCl is an atypical antipsychotic. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia and bipolar disorder. Olanzapine is structurally similar to clozapine and quetiapine. It is a dopamine antagonist and is classified as a thienobenzodiazepine.

Olanzapine/Samidorphan is a combination of olanzapine and the opioid receptor antagonist samidorphan is under development for the treatment of schizophrenia and bipolar I disorder. The single-tablet combination treatment is intended to provide the efficacy of olanzapine while mitigating olanzapine-associated weight gain.

Valproic acid-d14 (sodium) is the deuterated form of Valproic acid (sodium). Valproic acid sodium salt (Sodium Valproate) acts as an HDAC inhibitor, with an IC50 range of 0.5-2 mM, and inhibits the activity of HDAC1 (IC50, 400 μM) while also promoting the degradation of HDAC2. It activates the Notch1 signaling pathway and suppresses the proliferation of small cell lung cancer (SCLC) cells. Additionally, Valproic acid sodium salt is applicable in research related to epilepsy, bipolar disorder, and migraines.

Lurasidone-d8 HCl is a deuterated compound of Lurasidone HCl. Lurasidone HCl has a CAS number of 367514-88-3. Lurasidone hydrochloride is a thiazole derivative and atypical antipsychotic agent that functions as a dopamine D2 receptor antagonist; serotonin 5-HT2 receptor antagonist, serotonin 5-HT7 receptor antagonist, an antagonist of the adrenergic α2A and α2C receptors, as well as a partial serotonin 5-HT1A receptor agonist. It is used in the treatment of schizophrenia and bipolar disorder.

Valproic Acid (Standard) is a reference standard for research and analysis in studies involving Valproic Acid. Valproic Acid (2-Propylpentanoic Acid) is an HDAC inhibitor that suppresses HDAC1 activity and induces HDAC2 degradation, exhibiting oral bioavailability. Valproic Acid activates Notch1 signalling and inhibits the proliferation of small cell lung carcinoma cells, making it applicable for research into epilepsy and bipolar disorder.